INNATE PHARMA EUR0.05 financial statements, including revenue, expenses, profit, and loss
The total revenue of 0EVI for the last semiannual is 16.56 M EUR, and it's 53.15% lower compared to the previous semiannual. The net income of H2 23 is -9.29 M EUR.